Watch Ticker

Immatics N.V. Ordinary Shares

Go to Immatics N.V. Ordinary Shares Website

$6.34

-0.31 (-4.66%)

Live

Previous Close

$6.34

Day Range

$6.19 - $6.62

Previous Day Range

$6.51 - $6.66

Market Cap

$808.3 million USD

Day Vol.

352349

Previous Day Vol.

243055

Currency

USD

Primary Exchange

Nasdaq

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceu...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Delveinsight - TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight

The T-cell receptor (TCR) therapy pipeline is rapidly expanding, with over 80 pharmaceutical companies actively developing more than 100 TCR therapies for various cancers, including solid tumors. Several promising pipeline candidates are in different stages of clinical trials, showcasing the potential of TCR therapy to revolutionize cancer treatment.

Related tickers: IMCR, TCRX, IMTX, IMTXW.

Read Full Article

N/A - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Immatics announced positive clinical data for its TCR-T therapy candidates targeting PRAME, a protein frequently expressed in solid cancers. The data showed deep and durable responses in heavily pretreated patients, supporting the advancement of these therapies into late-stage development.

Related tickers: IMTX, IMTXW.

Read Full Article

Trending Tickers

Please sign in to view